Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $29,850.96 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Paul Kearney sold 4,078 shares of Sera Prognostics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $29,850.96. Following the transaction, the insider now directly owns 176,889 shares in the company, valued at approximately $1,294,827.48. The trade was a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sera Prognostics Stock Down 7.6 %

Shares of SERA opened at $6.44 on Friday. The firm’s 50 day moving average is $7.38 and its 200-day moving average is $7.64. Sera Prognostics, Inc. has a 12-month low of $1.67 and a 12-month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter last year, the business posted ($0.23) EPS. On average, research analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of institutional investors have recently bought and sold shares of SERA. RA Capital Management L.P. acquired a new position in shares of Sera Prognostics in the first quarter worth about $18,420,000. AWM Investment Company Inc. lifted its position in shares of Sera Prognostics by 56.0% in the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock valued at $5,320,000 after acquiring an additional 209,762 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after purchasing an additional 75,441 shares during the period. Ballentine Partners LLC purchased a new position in Sera Prognostics during the 2nd quarter worth approximately $294,000. Finally, Twelve Points Wealth Management LLC acquired a new stake in Sera Prognostics during the 2nd quarter valued at $257,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.